Orca Biosystems, Inc.: Clinical Trials

6 trials sponsored by Orca Biosystems, Inc., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 not yet recruiting, 2 recruiting. 6 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Active not recruiting 2, Not yet recruiting 2, Recruiting 2
Phase 21Recruiting 1

Follow Orca Biosystems, Inc.: new trials by email

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim - Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Phase 1Not yet recruitingUniversity of California, Davis202026-09-012026-08-12
A Study of Allogeneic Hematopoietic Cell Transplantation for Primary Progressive Multiple Sclerosis
Orca-Q, myeloablative regimen - Primary Progressive Multiple Sclerosis, Multiple Sclerosis
Phase 1Not yet recruitingStanford University102025-03-012025-03-28
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1 / Phase 2RecruitingUniversity of Florida402022-08-162026-10-30
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan - Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Phase 1Active not recruitingStanford University662021-09-072026-05-12
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Orca-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia
Phase 1Active not recruitingOrca Biosystems, Inc.1552019-11-212026-08-14
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
OrcaGraft (Orca-Q) - Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1RecruitingOrca Biosystems, Inc.3002019-04-082026-09-29

Conditions studied

Leukemia, Myeloid, Acute (3)  ·  Myelodysplastic Syndromes (3)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (3)  ·  Leukemia, Biphenotypic, Acute (2)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Disease (1)  ·  Hematologic Neoplasms (1)  ·  Leukemia, Myeloid, Accelerated Phase (1)  ·  Multiple Myeloma (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Myeloproliferative Disorders (1)

Interventions

Thiotepa (3)  ·  fludarabine (3)  ·  Busulfan (2)  ·  Granulocyte Colony-Stimulating Factor (2)  ·  Alkylating Agents (1)  ·  Cyclophosphamide (1)  ·  Filgrastim (1)  ·  Melphalan (1)  ·  Mycophenolic Acid (1)  ·  Sirolimus (1)  ·  Tacrolimus (1)  ·  fludarabine phosphate (1)  ·  plerixafor (1)  ·  ruxolitinib (1)

Countries

United States (5)

Top investigators

Everett Meyer, MD,PhD (1)  ·  James S McClellan, MD, PhD (1)  ·  Jordan Milner, MD (1)  ·  Mehrdad Abedi (1)

Results publications

PMID 39170618

NIH funding

P30CA093373 (1)